New BioMelbourne Network Board Appointment – Dr Elane Zelcer
15 November 2019 The BioMelbourne Network Board was delighted to welcome Dr Elane Zelcer as new Board Director at the most recent Annual General Meeting. Dr Elane Zelcer, Director, BioConsult Pty Ltd. Dr Elane Zelcer has extensive experience…
BioMelbourne Network is pleased to announce a collaboration with Australia China Health Accelerator
13 November 2019 UprAsia Founder Education Program – Elevate your startup’s Asia readiness About UprAsia Are you the founder or executive of a health technology startup or SME who recognise that Asian, especially Chinese markets, offer vast opportunity but…
Sienna and VivaZome to Evaluate EXO-NETTM for VivaZome’s Exosome-based Therapeutics
8 November 2019 Melbourne, Australia: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, has entered into an agreement with Melbourne-based VivaZome Therapeutics Pty Ltd…
Immutep presents positive interim data from Phase II TACTI-002 Trial at SITC
8 November 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reports positive interim data from its open label TACTI-002 Phase…
PI to manufacture Scinogy’s new cell processing system for cell therapy manufacture
8 November 2019 Planet Innovation is partnering with Melbourne-based start-up Scinogy to manufacture a revolutionary new cell processing system that is being commercialized by global biotechnology company Thermo Fisher Scientific. The Gibco™ CTS™ Rotea™ Counterflow Centrifugation System has the potential…
Weaning ourselves off opioids – Monash researchers use nanotechnology for pain relief
7 November 2019 Researchers at the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS) have created a nanoparticle that could improve the properties of painkillers by delivering…
Leading Australian health accelerator announces key commercial outcomes at global HLTH conference
30 October 2019 ANDHealth, Australia’s leading health technology accelerator which focuses solely on supporting the commercialisation of disruptive and digital health technologies, today announced the two year commercial growth outcomes of its first 10 ANDHealth+ cohort companies. Since…
Marketing email using BioMelbourne Network name – please ignore
1 November 2019 Some BioMelbourne Network members have received an email like this one using the BioMelbourne Network name. If you receive this or something similar, please ignore it. This has nothing to do with BioMelbourne Network and…
4Dx Celebrates Confirmatory Clinical Trial Success of its XV Lung Imaging Technology
29 October 2019 Melbourne, Australia, 29 October 2019 Australian medical technology company 4Dx Limited has attained excellent results in a major clinical trial of its patented four-dimensional lung imaging technology. The confirmatory clinical trial showed that XV Technology™…
Leading health executive appointed new Chair of ANDHealth
17 October 2019 One of Australia’s most experienced health sector executives, Gavin Fox-Smith, has been appointed the new Chair of leading digital health accelerator, ANDHealth, after Dr Anna Lavelle announced her retirement as Chair of the Board. Dr…
David Haylock, PhD Appointed as Chief Executive Officer
30 October 2019 Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is pleased to announce that Dr David Haylock has been appointed as Chief Executive Officer (CEO), effective as of 01 November, 2019. Dr Haylock has collaborated with VivaZome…
Victorian healthtech startups go-to-market in the USA
30 October 2019 Five Victorian medical device startups are better placed to take on the world after visiting Minnesota for the final Masterclass of BioMelbourne Network’s 2019 Healthtech Reimbursement program. Go-To-Market in the USA was a three-day experiential…
